Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Cancer Centre, Singapore
With
Guardant Health AMEA, Inc.
Age
21–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with advanced ALK fusion oncogene positive lung adenocarcinoma that have progressed after 1-2 ALK inhibitors, with at least one prior line of 2nd generation ALKi (i.e. Ceritinib, Alectinib, Brigatinib or Ensartinib)
The availability of sufficient plasma
Age ≥ 21 years
WHO performance status ≤ 2
Life expectancy of ≥ 21 weeks
Patients should have adequate organ function for potential consideration into clinical trials (routine blood tests are valid within 14 days before enrollment):
1. Adequate bone marrow function as shown by: ANC ≥ 1.0x10\^9/L, Platelets ≥ 75x10\^9/L, Hb ≥ 7.5 g/dL
2. Alanine aminotransferase (ALT) and aspirate aminotransferase (AST) normal range (or ≤ 3.0xULN if liver metastases are present)
Willing to provide signed informed consent
Patients whom do not fulfill the above criteria may be discussed on a case-by-case basis within the study team, for potential enrolment
You may not be if
Received more than 2 prior ALK inhibitors (ALKi)
Symptomatic or uncontrolled brain metastases requiring concurrent treatment inclusive but not limited to surgery and radiation. Stable/ tailing doses of corticosteroids is permitted
Clareo Health | Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC
